Syensqo SA
XBRU:SYENS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67.83
105.32
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Syensqo SA
Total Current Liabilities
Syensqo SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Syensqo SA
XBRU:SYENS
|
Total Current Liabilities
€1.8B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Umicore SA
XBRU:UMI
|
Total Current Liabilities
€3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Syensqo SA
Glance View
Syensqo SA stands at the forefront of the biotechnology sector, driven by a vision to revolutionize disease treatment through advanced therapeutic solutions. Founded in the heart of an innovation hub, the company specializes in developing cutting-edge synthetic biology applications aimed at enhancing drug efficacy and reducing side effects. With a dynamic pipeline populated by promising drug candidates in various stages of clinical trials, Syensqo is harnessing the power of gene editing and novel delivery systems, creating a compelling narrative of growth and potential. Its strategic partnerships with leading research institutions and pharmaceutical companies underscore a commitment to collaboration and innovation, positioning Syensqo as a promising player in an ever-evolving market. For investors, Syensqo SA embodies both opportunity and sustainability. The company’s robust intellectual property portfolio not only protects its innovations but also provides a competitive edge in emerging markets. With a dedicated team of scientists and industry veterans at the helm, Syensqo is primed to navigate the complexities of regulatory landscapes while leveraging data-driven insights to guide decision-making. As the global demand for effective healthcare solutions escalates, Syensqo's commitment to sustainable practices and ethical drug development resonates strongly with socially conscious investors. By investing in Syensqo, stakeholders are not only placing their capital in a high-growth venture but also participating in a transformative journey toward groundbreaking healthcare advancements.
See Also
What is Syensqo SA's Total Current Liabilities?
Total Current Liabilities
1.8B
EUR
Based on the financial report for Dec 31, 2023, Syensqo SA's Total Current Liabilities amounts to 1.8B EUR.
What is Syensqo SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
-27%
Over the last year, the Total Current Liabilities growth was -68%. The average annual Total Current Liabilities growth rates for Syensqo SA have been -27% over the past three years .
You don't have any saved screeners yet
